Page 33 - 2021年14期
P. 33

[ 4 ]  陈冠新,文彬,孙海涛,等.鳖甲煎丸对 CCl4致大鼠肝纤                     2018,136(3):133-141.
             维化模型中NF-κB信号通路的影响[J].中国实验方剂学                  [19]  BU F T,CHEN Y,YU H X,et al. SENP2 alleviates
             杂志,2018,24(10):161-167.                            CCl4-induced liver fibrosis by promoting activated hepatic
        [ 5 ]  张定棋,徐莹,杨海琳,等.不同制法下瘀血汤对 CCl4诱                     stellate cell apoptosis and reversion[J]. Toxicol Lett,2018,
             导大鼠肝纤维化的影响[J].中国实验方剂学杂志,2020,                      289:86-98.
             26(5):18-25.                                  [20]  CHEN Y,LI R,HU N,et al. Baihe Wuyao decoction ame-
        [ 6 ]  王乾宇,王文佳,奚锦,等.杜仲多糖对肝纤维化模型大鼠                       liorates CCl4-induced chronic liver injury and liver fibro-
             Ⅰ、Ⅲ型胶原蛋白,MMP-1,TIMP-1及TGF-β 1 mRNA表                sis in mice through blocking TGF-β 1/Smad2/3 signaling,
             达的影响[J].中国实验方剂学杂志,2018,24(23):153-                 anti-inflammation and anti-oxidation effects[J]. J Ethno-
             158.                                               pharmacol,2020,263:113227.
        [ 7 ]  国家中医药管理局《中华本草》编委会.中华本草:第 10                 [21]  许琼梅,李跃龙,曹后康,等.溪黄草水提物对四氯化碳诱
             卷[M].上海:上海科学技术出版社,2009:56-57.                      导大鼠肝纤维化的保护作用及机制研究[J].中国药房,
        [ 8 ]  刘慧,孟爱荣,彭春喜,等.黄水枝属药学研究概况[J].安                     2018,29(20):2791-2796.
             徽农业科学,2014,42(35):12472-12473.
                                                           [22]  ZHU Z,HU R,LI J,et al. Alpinetin exerts anti-inflamma-
        [ 9 ]  唐爱存,韦燕飞,刘喜华,等.葫芦茶苷对四氯化碳致肝纤
                                                                tory,anti-oxidative and anti-angiogenic effects through ac-
             维化模型小鼠的保护作用及机制研究[J].中国药房,
                                                                tivating the Nrf2 pathway and inhibiting NLRP3 pathway
             2020,31(2):190-195.
                                                                in carbon tetrachloride-induced liver fibrosis[J]. Int Immu-
        [10]  徐列明,刘平,沈锡中,等.肝纤维化中西医结合诊疗指
                                                                nopharmacol,2021,96:107660.
             南:2019 年版[J].临床肝胆病杂志,2019,35(7):1444-
                                                           [23]  李小侠.血清谷氨酸脱氢酶与其他肝功能指标联合检测
             1449.
                                                                在肝病诊断中的临床意义[J].陕西医学杂志,2020,49
        [11]  HUANG Y,DENG X,LIANG J. Modulation of hepatic
                                                                (12):143-146.
             stellate cells and reversibility of hepatic fibrosis[J]. Exp
                                                           [24]  NALLAGANGULAK S,NAGARAJ S K,VENKATASWAMY
             Cell Res,2017,352(2):420-426.
                                                                L,et al. Liver fibrosis:a compilation on the biomarkers
        [12]  贾继东,魏来,侯金林,等.《中国肝病诊疗管理规范》白皮
                                                                status and their significance during disease progression[J].
             书:节选[J].临床肝胆病杂志,2014,30(3):197-209.
                                                                Future Sci OA,2018,4(1):FSO250.
        [13]  DU Q H,ZHANG C J,LI W H,et al. Gan shen fu fang
                                                           [25]  GRESSNER O A,WEISKIRCHEN R,GRESSNER A M.
             ameliorates liver fibrosis in vitro and in vivo by inhibiting
                                                                Biomarkers of liver fibrosis:clinical translation of mole-
             the inflammatory response and extracellular signal-regula-
                                                                cular pathogenesis or based on liver-dependent malfunction
             ted kinase phosphorylation[J]. World J Gastroenterol,2020,
             26(21):2810-2820.                                  tests[J]. Clinica Chimica Acta,2007,381(2):107-113.
        [14]  CZAJA A J. Hepatic inflammation and progressive liver fi-  [26]  CEQUERA A,GARCÍA DE LEÓN MÉNDEZ M C. Bio-
             brosis in chronic liver disease[J]. World J Gastroenterol,  markers for liver fibrosis:advances,advantages and dis-
             2014,20(10):2515-2532.                             advantages[J]. Rev Gastroenterol Méx,2014,79(3):187-
        [15]  XU F,LIU C,ZHOU D,et al. TGF-β/SMAD pathway and   199.
             its regulation in hepatic fibrosis[J]. Eur J Histochem,2016,  [27]  GUO Y,LIANG X,MENG M,et al.Hepatoprotective ef-
             64(3):157-167.                                     fects of Yulangsan flavone against carbon tetrachloride
        [16]  吴姗姗,王振常,黎妍,等.中药复方壮肝逐瘀煎对肝纤维                        (CCl4 )-induced hepatic fibrosis in rats[J]. Phytomedicine,
             化模型大鼠微循环的影响[J].中华中医药学刊,2020,38                     2017,33:28-35.
            (1):151-156,277.                               [28]  杨婧,贾彦,王蔚,等.膈下逐瘀汤对大鼠纤维化肝脏组织
        [17]  WANG R,ZHANG H,WANG Y,et al. Inhibitory effects   谷胱甘肽抗氧化系统的影响[J].中国实验方剂学杂志,
             of quercetin on the progression of liver fibrosis through  2017,23(17):129-134.
             the regulation of NF-кB/IкBα,p38 MAPK,and Bcl-2/Bax  [29]  JIANG Y,XIANG C,ZHONG F,et al. Histone H3K27
             signaling[J]. Int Immunopharmacol,2017,47:126-133.  methyltransferase EZH2 and demethylase JMJD3 regulate
        [18]  SUN H,CHEN G,WEN B,et al. Oligo-peptide I-C-F-6 in-  hepatic stellate cells activation and liver fibrosis[J]. The-
             hibits hepatic stellate cell activation and ameliorates  ranostics,2020,11(1):361-378.
             CCl4-induced liver fibrosis by suppressing NF-κ B signa-     (收稿日期:2021-03-31  修回日期:2021-05-27)
             ling and Wnt/β-catenin signaling[J]. J Pharmacol Sci,                              (编辑:邹丽娟)




        中国药房    2021年第32卷第14期                                            China Pharmacy 2021 Vol. 32 No. 14  ·1691 ·
   28   29   30   31   32   33   34   35   36   37   38